ATE481109T1 - Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden - Google Patents
Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werdenInfo
- Publication number
- ATE481109T1 ATE481109T1 AT02773789T AT02773789T ATE481109T1 AT E481109 T1 ATE481109 T1 AT E481109T1 AT 02773789 T AT02773789 T AT 02773789T AT 02773789 T AT02773789 T AT 02773789T AT E481109 T1 ATE481109 T1 AT E481109T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- hiv
- antibody fragments
- nucleic acids
- env
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 230000037029 cross reaction Effects 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32970901P | 2001-10-16 | 2001-10-16 | |
PCT/US2002/033165 WO2003033666A2 (en) | 2001-10-16 | 2002-10-16 | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE481109T1 true ATE481109T1 (de) | 2010-10-15 |
Family
ID=23286644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02773789T ATE481109T1 (de) | 2001-10-16 | 2002-10-16 | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden |
Country Status (7)
Country | Link |
---|---|
US (2) | US7223844B2 (de) |
EP (1) | EP1450857B1 (de) |
AT (1) | ATE481109T1 (de) |
AU (1) | AU2002337885B1 (de) |
CA (1) | CA2463931A1 (de) |
DE (1) | DE60237704D1 (de) |
WO (1) | WO2003033666A2 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951947B2 (en) | 2000-07-13 | 2005-10-04 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
US7176037B2 (en) | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
ATE481109T1 (de) | 2001-10-16 | 2010-10-15 | Us Gov Health & Human Serv | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden |
US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
WO2003087324A2 (en) * | 2002-04-09 | 2003-10-23 | Children's Hospital, Inc. | Antibody gene transfer and recombinant aav |
CA2485120C (en) * | 2002-05-06 | 2013-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
EP1554392A4 (de) * | 2002-05-06 | 2007-08-08 | Us Gov Health & Human Serv | Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken |
GB0218817D0 (en) * | 2002-08-13 | 2002-09-18 | San Raffaele Centro Fond | Pharmaceutical compounds |
EP1627046A4 (de) * | 2003-05-06 | 2008-02-13 | Scripps Research Inst | Bindungsmoleküle mit domänenaustausch, verwendungsverfahren und herstellungsverfahren |
WO2006071206A2 (en) * | 2003-09-29 | 2006-07-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunoglobulins whith potent and broad antiviral activity |
WO2005088308A2 (en) * | 2004-03-12 | 2005-09-22 | The Scripps Research Institute | Fluorescent signal emitting live cell biosensor molecules and dyes for detection and quantification of protein activities |
US8637234B2 (en) | 2004-04-16 | 2014-01-28 | Uab Research Foundation | Molecular scaffolds for HIV-1 epitopes |
WO2006044410A2 (en) * | 2004-10-14 | 2006-04-27 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines |
US8647818B2 (en) | 2005-02-18 | 2014-02-11 | UAB Research Foundation, University of Alabama—Birmingham | Molecular scaffolds for HIV-1 immunogens |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
ES2438019T3 (es) * | 2005-07-22 | 2014-01-15 | Cytodyn, Inc. | Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1 |
MX2009001204A (es) | 2006-08-17 | 2009-02-11 | Hoffmann La Roche | Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico. |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
CN101516914A (zh) | 2006-09-29 | 2009-08-26 | 霍夫曼-拉罗奇有限公司 | 针对ccr5的抗体及其应用 |
EP2073840A4 (de) * | 2006-10-23 | 2010-10-27 | Progenics Pharm Inc | Modifizierte gp140-hüllpolypeptide von hiv-1-isolaten, zusammensetzungen, stabilisierten trimeren komplexen und ihre verwendungen |
TW200902544A (en) | 2007-03-13 | 2009-01-16 | Hoffmann La Roche | Peptide-complement conjugates |
US20090074766A1 (en) * | 2007-09-14 | 2009-03-19 | Ketas Thomas J | Methods of inhibiting HIV-2 infection |
AU2010234031B2 (en) | 2009-04-07 | 2015-10-01 | Roche Glycart Ag | Trivalent, bispecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
MX339622B (es) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Diacuerpos covalentes y sus usos. |
EP2609112B1 (de) * | 2010-08-24 | 2017-11-22 | Roche Glycart AG | Aktivierbare bispezifische antikörper |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
AU2011312562B2 (en) * | 2010-09-27 | 2014-10-09 | Sangamo Therapeutics, Inc. | Methods and compositions for inhibiting viral entry into cells |
RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
RS58765B1 (sr) | 2011-05-21 | 2019-06-28 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
RU2721707C2 (ru) | 2013-03-14 | 2020-05-21 | Макродженикс, Инк. | Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор |
US9951118B2 (en) * | 2013-08-02 | 2018-04-24 | The Regents Of The University Of California | Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
EP2839842A1 (de) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon |
EP2840091A1 (de) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
JP2017501970A (ja) * | 2013-12-10 | 2017-01-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 薬学的活性エンティティのマルチサブユニット構造への標的特異的送達のためのマルチサブユニット構造のサブユニットの結合ドメインの使用 |
KR20160135190A (ko) | 2014-02-14 | 2016-11-25 | 앤드류 에스. 카이 | 혈관형성 암의 치료를 위한 개선된 방법 |
EP3201227A4 (de) | 2014-09-29 | 2018-04-18 | Duke University | Bispezifische moleküle mit einem hiv-1-hüll-targeting-arm |
EP3227332B1 (de) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispezifische antikörper |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
WO2018237357A1 (en) | 2017-06-22 | 2018-12-27 | University Of Maryland, Baltimore | HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV |
WO2019173794A1 (en) * | 2018-03-09 | 2019-09-12 | Atreca, Inc. | Anti-hiv antibodies |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
WO1993015747A1 (en) | 1992-02-10 | 1993-08-19 | Progenics Pharmaceuticals, Inc. | A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission |
ES2194015T3 (es) | 1992-09-30 | 2003-11-16 | Scripps Research Inst | Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana. |
US5652138A (en) | 1992-09-30 | 1997-07-29 | The Scripps Research Institute | Human neutralizing monoclonal antibodies to human immunodeficiency virus |
US5925741A (en) | 1992-12-31 | 1999-07-20 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Antibodies directed against binding-associated epitopes |
JPH08510246A (ja) * | 1993-05-07 | 1996-10-29 | アクゾ・ノベル・エヌ・ベー | Hiv免疫原性複合体 |
AU8083594A (en) | 1993-10-19 | 1995-05-08 | Scripps Research Institute, The | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
CA2204863A1 (en) | 1994-11-10 | 1996-05-23 | Dennis R. Burton | Method for identifying protective antigens for eliciting neutralizing antibodies |
PT1012259E (pt) | 1997-06-04 | 2009-11-06 | Oxford Biomedica Ltd | Vector dirigido a tumor |
WO1999024465A1 (en) | 1997-11-10 | 1999-05-20 | Dana-Farber Cancer Institute | Stabilized primate lentivirus envelope glycoproteins |
US6135941A (en) | 1998-03-27 | 2000-10-24 | Incyte Pharmaceuticals, Inc. | Human immune system associated molecules |
AU2604200A (en) | 1999-01-08 | 2000-07-24 | Panacos Pharmaceuticals, Inc. | Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41 |
EP1161455B1 (de) | 1999-03-16 | 2008-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion |
DK2067788T3 (da) | 1999-05-18 | 2015-10-19 | Dyax Corp | Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf |
GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
CN1505528A (zh) | 2000-09-22 | 2004-06-16 | �ſ���ѧ��˾ | 包含结合hiv包膜蛋白的配体的免疫原 |
US7666424B2 (en) | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
DE10123041A1 (de) | 2001-05-11 | 2002-11-28 | Tobias Heintges | Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
ATE481109T1 (de) | 2001-10-16 | 2010-10-15 | Us Gov Health & Human Serv | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden |
CA2485120C (en) * | 2002-05-06 | 2013-02-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
EP1554392A4 (de) | 2002-05-06 | 2007-08-08 | Us Gov Health & Human Serv | Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken |
-
2002
- 2002-10-16 AT AT02773789T patent/ATE481109T1/de not_active IP Right Cessation
- 2002-10-16 WO PCT/US2002/033165 patent/WO2003033666A2/en active Search and Examination
- 2002-10-16 CA CA002463931A patent/CA2463931A1/en not_active Abandoned
- 2002-10-16 AU AU2002337885A patent/AU2002337885B1/en not_active Ceased
- 2002-10-16 US US10/492,729 patent/US7223844B2/en not_active Expired - Fee Related
- 2002-10-16 EP EP02773789A patent/EP1450857B1/de not_active Expired - Lifetime
- 2002-10-16 DE DE60237704T patent/DE60237704D1/de not_active Expired - Lifetime
-
2007
- 2007-05-15 US US11/748,992 patent/US7378093B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1450857A4 (de) | 2006-01-18 |
US20040259075A1 (en) | 2004-12-23 |
US7223844B2 (en) | 2007-05-29 |
DE60237704D1 (de) | 2010-10-28 |
US20070212349A1 (en) | 2007-09-13 |
AU2002337885B1 (en) | 2003-04-28 |
WO2003033666A2 (en) | 2003-04-24 |
WO2003033666A3 (en) | 2004-06-24 |
CA2463931A1 (en) | 2003-04-24 |
EP1450857B1 (de) | 2010-09-15 |
US7378093B2 (en) | 2008-05-27 |
EP1450857A2 (de) | 2004-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE481109T1 (de) | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden | |
WO2005000244A3 (en) | Methods and compositions for treating rheumatoid arthritis | |
EP2400021A3 (de) | Verfahren und Zusammensetzungen auf ErbB3-Basis zur Behandlung von Neoplasmen | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
WO2003048083A3 (en) | Antibodies against monocyte chemotactic proteins | |
AU9399501A (en) | Therapeutic antibodies | |
DE60219801D1 (de) | KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN | |
PE20071055A1 (es) | Anticuerpos anti mn | |
DE502005006022D1 (de) | Amphotere ethylmethacrylat-copolymere und deren verwendung | |
ATE404587T1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
WO2003092624A3 (en) | Use of heat shock proteins to enhance efficacy of antibody therapeutics | |
WO2003025019A8 (en) | Anti-pdgf antibodies and methods for producing engineered antibodies | |
BR9709958A (pt) | Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso | |
DE60238555D1 (de) | Parathormon-antikörper und damit zusammenhängende verfahren | |
EA200400134A1 (ru) | Терапевтический агент | |
BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
WO2004067564B1 (en) | Compositions against cancer antigen liv-1 and uses thereof | |
EP0972054A4 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
WO2004037997A3 (en) | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof | |
WO2003068813A3 (en) | Group b streptococcus antigen | |
EP1759007A4 (de) | Proteinkomplexierungsverfahren mittels dispersionssystem und proteine daraus | |
WO2005072380A3 (en) | Membrane attack complexes associated with circulating immune complexes | |
ES2013321A6 (es) | Un metodo de produccion de anticuerpos monoclonales | |
WO2002100343A3 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
DK1423525T3 (da) | Rekombinant MVA, der kan eksprimere HCV-strukturantigener |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |